Journal article
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
Abstract
Background: Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-line immune checkpoint inhibitor (ICI) combinations have demonstrated a significant survival benefit. Methods: A systematic search of the published …
Authors
Lalani AKA; Heng DYC; Basappa NS; Wood L; Iqbal N; McLeod D; Soulières D; Kollmannsberger C
Journal
Therapeutic Advances in Medical Oncology, Vol. 14, ,
Publication Date
June 28, 2022
DOI
10.1177/17588359221108685
ISSN
1758-8340